Nanjing Sanhome Pharmaceutical, Co., Ltd.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer. | HR+ / HER2- Advanced Breast Cancer | Active, not recruiting | Phase 1 | 2026-04-29 | NCT07557004 | |
| A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2026-02-09 | NCT07392866 | |
| A Study of SH009 Injection in Patients With Advanced Solid Tumors. | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastric neoplasm, liver disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder | Recruiting | Phase 1 | 2026-02-05 | NCT07390838 | |
| A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, liver cancer, liver disorder, neoplasm | Active, not recruiting | Phase 1 | 2026-01-23 | NCT07362264 | |
| SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2023-10-12 | NCT06080776 |